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Abstract To compare rheumatologists’ adherence to treat-
ment protocols for rheumatoid arthritis (RA) targeted at
Disease Activity Score (DAS) ≤2.4 or <1.6. The BeSt-study
enrolled 508 early RA (1987) patients targeted at DAS ≤2.4.
The IMPROVED-study included 479 early RA (2010) and
122 undifferentiated arthritis patients targeted at DAS <1.6.
We evaluated rheumatologists’ adherence to the protocols and
assessed associated opinions and conditions during 5 years.
Protocol adherence was higher in BeSt than in IMPROVED
(86 and 70 %), with a greater decrease in IMPROVED (from
100 to 48 %) than in BeSt (100 to 72 %). In BeSt, 50 % of
non-adherence was against treatment intensification/restart,
compared to 63 % in IMPROVED and 50 vs. 37 % were
against tapering/discontinuation. In both studies, non-
adherence was associated with physicians’ disagreement with
DAS or with next treatment step and if patient’s visual ana-
logue scale (VAS) for general health was ≥20 mm higher than
the physician’s VAS. In IMPROVED, also discrepancies be-
tween swelling, pain, erythrocyte sedimentation rate, and
VASgh were associated with non-adherence. Adherence to
DAS steered treatment protocols was high but decreased over
5 years, more in a DAS <1.6 steered protocol. Non-adherence
was more likely if physicians disagreed with DAS or next
treatment step. In the DAS <1.6 steered protocol, non-
adherence was also associated with discrepancies between
subjective and (semi)objective disease outcomes, and often
against required treatment intensification. These results may
indicate that adherence to DAS-steered protocols appears to
depend in part on the height of the target and on how physi-
cians perceive the DAS reflects RA activity.
Keywords DAS steered protocols . Early rheumatoid
arthritis . Physician . Protocol adherence . Treatment target
Introduction
The optimal treatment strategy to suppress disease activity in
early arthritis patients is by initial combination therapy follow-
ed by targeted treatment [1–7]. Although in clinical trials,
treat-to-target therapy has been already widely used, imple-
mentation in daily practice appears to be difficult [8–10].
Furthermore, it is unknown what the optimum treatment target
is. It is recommended to aim at disease activity score (DAS)-
remission (<1.6) or low disease activity (DAS <2.4). [11] A
lower disease activity seems to be the optimal treatment target
with better disease outcomes. [4, 7] However, achieving lower
DAS and having better disease outcomes may not be causally
related but results of mutually interdependent qualities or
characteristics. Remission, especially by the strictest
Trial registration
BeSt-study: [NTR262, NTR 265 (Dutch trial registry)] IMPROVED-
study: [ISRCTN Register number 11916566 and EudraCT number 2006
06186-16]
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definition, can be difficult to achieve in daily practice.
Moreover, steering at remission when disease activity is al-
ready low can lead to more costs and side effects with no
added clinical benefit. Rheumatologists may be reluctant to
aim for remission if disease activity is already substantially
decreased from baseline, especially if they feel that the mea-
sured DAS is falsely elevated due to symptoms or inflamma-
tion not caused by rheumatoid disease activity.
We tried to estimate rheumatologists’ willingness and ar-
guments to treat-to-target if the target was low disease activity
or DAS-remission by comparing two clinical trials in patients
with RAwhere the treatment targets were DAS ≤2.4 and DAS
<1.6. The BeSt-study, a multicenter randomized clinical trial
set up in the year 2000, when treat-to-target was not yet part of
daily practice. Four different treatment strategies were
assessed in early rheumatoid arthritis (RA) patients aiming at
low disease activity (DAS ≤2.4). Seven years later in rheuma-
tology centers who also participated in the BeSt-study, the
IMPROVED-study started, a randomized clinical trial. Early
RA and undifferentiated arthritis (UA) patients were treated
with methotrexate (MTX) and tapered high dose of predni-
sone followed by treatment targeted at DAS-remission (DAS
<1.6). To investigate whether these treatment targets can be
equally well implemented in daily practice, we compared
rheumatologists’ adherence to these DAS-steered treatment
protocols targeted at either DAS ≤2.4 or DAS <1.6 and
assessed associated opinions of the rheumatologists and con-
ditions that may result in non-adherence by the rheumatologist
during 5 years follow-up.
Materials and methods
Study design and patients
The BeSt-study (Dutch acronym for treatment strategies) was
a multicenter, randomized, clinical trial started in 20 hospitals
in the Netherlands in the year 2000, when treat-to-target was
not daily practice. The aim was to evaluate the efficacy of four
treatment strategies in 508 early active RA according to the
1987American College of Rheumatology (ACR) criteria [12].
Every 3 months, the DAS was measured and calculated by the
research nurse, and treatment adjustments were initiated by
the rheumatologist targeted at low disease activity (DAS
≤2.4). If patients did not achieve low disease activity, the next
treatment step was taken (supplementary Fig. 1). If the DAS
was ≤2.4 for at least 6 months, medication was tapered to a
maintenance dose. From year 2, if next the DAS was <1.6 for
at least 6 months, medication was discontinued, but when the
DAS was ≥1.6 medication was restarted, and subsequently
increased or tapered depending on the DAS as mentioned
above. The study was approved by the Medical Ethics
Committee of each participating center and all patients gave
written informed consent. More details about the BeSt-study
were previously published [3, 5].
The IMPROVED-study (acronym for Induction therapy
with MTX and prednisone in rheumatoid or very early arthrit-
ic disease) was a multicenter, randomized, clinical trial started
in 2007 in 12 hospitals in the western part of the Netherlands,
who also participated in the BeSt-study. 479 early RA accord-
ing to the 2010 ACR and European League Against
Rheumatism (EULAR) classification criteria [13] and 122
UA patients, started with induction therapy with MTX and
tapered high dose of prednisone followed by 4-monthly treat-
ment targeted at DAS-remission (<1.6). If patients were in
DAS-remission, the medication was tapered and finally
stopped but if DAS was >1.6, the medication was intensified
or restarted (supplementary Fig. 2). All patients gave written
informed consent and the Medical Ethical Committee of each
participating center approved the study protocol. Details about
the IMPROVED-study were published elsewhere. [4, 7].
Measurements
All treatment steps in both studies were recorded in two dif-
ferent databases. We evaluated whether each treatment step
was by protocol or not. Every study visit, the rheumatologist
was asked to fill out a brief questionnaire about satisfaction
with the effect of treatment, agreement with the required treat-
ment step, and agreement with the DAS (Table 1). Also, the
rheumatologists recorded their estimation of the patient’s dis-
ease activity on a visual analogue scale (VASphys, 0–100mm,
0= inactive, 100= most active).
Five hypothetical conditions were formulated that may
have an effect in the decision process of the rheumatologist
to take a treatment step not by protocol [14]. These conditions
aim to represent likely discrepancies between synovitis ob-
served at physical examination and reported pain at physical
examination or signs of inflammation in the laboratory analy-
sis and discrepancies between the VASphys and the VAS for
global health by the patient (VASgh) as used in calculation of
the DAS (Table 1).
Statistical analyses
Data of 5 years follow-up from both studies were used. Both
studies were compared for frequency of adherence and protocol
violations using descriptive statistics. A generalized linear mixed
model (GLMM) for each study was used to evaluate: the asso-
ciation between protocol violations and the answers to the rheu-
matologists’ questionnaire; the association between protocol vi-
olations (dependent) and the presence of the hypothetical condi-
tions (independent); the association between the (dis)agreement
with the DAS as filled out in the questionnaire by the rheuma-
tologist (dependent) and the presence of the hypothetical condi-
tions (independent); the association between the (dis)agreement
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with the DAS as filled out on the questionnaire by the rheuma-
tologist (dependent) and DAS categories (independent) (For the
BeSt-study, three DAS categories were used (DAS-remission
<1.6, low disease activity ≥1.6 ≤ 2.4, and high disease activity
>2.4) and for the IMPROVED-study, two categories were used
(DAS-remission <1.6, and no DAS-remission ≥1.6)); the associ-
ation between physician’s satisfaction with how effect of treat-
ment (dependent) and DAS categories as mentioned above (in-
dependent). An autoregressive moving average was used for the
correlation matrix in both studies that assumes that observations
that are further apart are less strongly correlated. Statistical anal-
yses were performed with SPSS for Windows version 23.0.
Results
Protocol adherence and violations
Frequencies of protocol adherence and violations per visit
during 5 years follow-up are shown in Fig. 1a for the BeSt-
study and in Fig. 2a for the IMPROVED-study. Of the visit at
t = 5 years, data were available for 82 % of patients in the
BeSt-study and in 73 % in the IMPROVED-study.
Rheumatologists’ adherence to the protocol was greater in
the BeSt-study than in the IMPROVED-study in completed
visits up to the fifth year (mean over time 86 and 70 %,
Table 1 A. brief questionnaire filled out by the physician at every visit, B. five hypothetical conditions. SJC swollen joint count; TJC tender joint
count; ESR erythrocyte sedimentation rate; VASgh visual analogue scale general health of the patient;VASphys visual analogue scale general health of the
patient filled out by the physician
A.
1. Are you sasﬁed with the eﬀect of the treatment on the rheumatoid arthris 
(undiﬀerenated arthris) in this paent?
Yes
No, the disease is not suﬃciently suppressed
2. Do you think the DAS adequately represents the disease acvity in this paent?
Yes, the situaon is well represented by the DAS
No, the paent is doing beer than the DAS represents
No, the paent is doing worse than the DAS represents
3. Are you sasﬁed with the next treatment step?
Yes, I would have taken the same (or comparable) step
No, I would have treated the paent as follows: …
B.
Condition 1 SJC ≤1 and TJC ≥2
Condition 2 SJC ≤1 and ESR ≥28
Condition 3 SJC ≤1 and VASgh ≥20 mm
Condition 4 VASgh ≥20 mm higher than VASphys
Condition 5 VASphys ≥20 mm higher than VASgh
SJC: swollen joint count; TJC: tender joint count; ESR: erythrocyte sedimentation rate; VASgh: visual analogue scale 
general health of the patient; VASphys: visual analogue scale general health of the patient filled out by the physician.
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respectively). Protocol adherence decreased over time from
100 to 72 % in the BeSt-study and from 100 to 48 % in the
IMPROVED-study. Protocol violations could entail either
omitting to restart or intensify medication (as required if
DAS was above treatment target: high DAS protocol viola-
tion) or omitting to taper or stop (as required if DAS was
below treatment target: low DAS protocol violation). Of all
protocol violations in the BeSt-study, 50 % were low-DAS
protocol violations and 50 % were high-DAS protocol viola-
tions. In case of a high-DAS protocol violation, the measured
DAS was (median) 0.6 (interquartile range IQR 0.3;1.2)
higher than the target DAS, whereas the difference was 0.9
(0.4;1.6) when the protocol for high DAS was followed
(Table 2). In case of a low-DAS protocol violation, the mea-
sured DASwas 0.7 (−1.2;-0.3) below the target DAS, whereas
the difference was −0.9 (−1.4;-0.5) when the protocol for low
DAS was followed. Patients’ age was associated with more
high-DAS protocol violations (1.02 (1.01–1.03)), and gender
showed a trend (female gender 1.44 (0.94–2.21)), but these
associations were not found for low-DAS protocol violations.
There was no difference in protocol violations between the
treatment arms (p = 0.872). In both studies, physicians in the
peripheral centers had higher adherence compared to those in
the two university centers (BeSt-study 95 % peripheral vs
87 % university and IMPROVED-study 94 vs. 66 %,
respectively).
Of all protocol violations in the IMPROVED-study, 63 %
were high-DAS protocol violations and 37 % were low-DAS
protocol violations. In case of a high-DAS protocol violation,
the measured DAS was (median) 0.5 (IQR 0.2;0.9) higher
Fig. 1 Protocol adherence and violations in the BeSt-study and answers of
the rheumatologist to the questionnaire. a: protocol adherence was evalu-
ated every visit; b: question was asked every visit from the tenth visit in
year 3 until the end of follow-up; c: question was asked every visit from the
second visit until the end of follow-up; d: question was asked every visit
from the second visit until the end of follow-up.DAS disease activity score
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Fig. 2 Protocol adherence and violations in the IMPROVED-study and
answers of the rheumatologist to the questionnaire. a: protocol adherence
was evaluated every visit; b: question was asked every visit from the
second visit and after the second year only at yearly visits; c: question
was asked every visit from the second visit and after the second year only
at yearly visits; d: question was asked every visit from the second visit
until the seventh visit. DAS disease activity score
Table 2 Differences with DAS-target in protocol violations (high-DAS or low-DAS) and no protocol violations
BeSt-study target 2.4 IMPROVED-study Target 1.6
High DAS PV No PV Low DAS PV No PV High DAS PV No PV Low DAS PV No PV





























DAS disease activity score, PV protocol violation, mDAS measured DAS, tDAS target DAS
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than the target DAS, whereas the difference was 0.7 (0.3;1.2)
when the protocol for high DAS was followed. In case of a
low-DAS protocol violation, the measured DAS was −0.6
(−0.9;−0.3) lower than the target DAS, whereas the difference
was −0.7 (−1.0;−0.4) when the protocol for low DAS was
followed. Patient’s gender was associated with high-DAS pro-
tocol violations (OR for females 1.53 (1.23–1.90)) and age
showed a trend (1.01 (1.00–1.02)). Age and gender were not
associated with low-DAS protocol violations. Diagnosis of
RA (OR 1.47 (1.05–2.06)) and treatment group (arm 1 OR
2.07 (1.36–3.13) and arm 2 OR 1.87 (1.21–2.87)) were asso-
ciated with more low DAS-protocol violations, and diagnosis
RA was associated with fewer high-DAS protocol violations
(OR 0.73 (0.56–0.95)). Both arm 1 (OR 1.44 (1.13–1.85)) and
arm 2 (1.69 (1.31–2.19)) were also associated with more high-
DAS protocol violations in the IMPROVED-study. As ex-
pected, there were more protocol violations in the outside of
protocol group (OR for high-DAS protocol violations 2.84
(2.05–3.94)).
In the BeSt-study, rheumatologists were more likely not to
follow the protocol if they were not satisfied with the current
treatment effect (OR (95 % CI) 1.36 (1.08–1.71)), disagreed
with how the DAS represented actual disease activity (2.26
(1.84–2.78) when they thought the DAS overestimated dis-
ease activity and 2.82 (2.08–3.81) when they thought the DAS
underestimated disease activity), were not satisfied with the
current treatment effect (OR (95 % CI) 1.36 (1.08–1.71)) or
disagreed with the next treatment step (2.77 (2.34–3.28))
(Table 3). However, in 346/463 (75 %) visits where the rheu-
matologist was not satisfied with the current treatment effect
the protocol was still followed, as also occurred in 714/939
(76%) visits where the rheumatologist disagreed with how the
DAS represented actual disease activity, and in 832/1070
(78 %) visits where the rheumatologist did not agree with
the next treatment step.
Compared to the BeSt-study, in the IMPROVED-study a
protocol violation appeared even more likely if rheumatolo-
gists disagreed with how the DAS represented actual disease
activity (5.97 (4.82–7.40) if they thought the DAS
overestimated disease activity and 1.44 (1.01–2.07) if they
thought the DAS underestimated disease activity) or disagreed
with the next treatment step (3.53 (2.84–4.37)). However, if
they were not satisfied with the current treatment effect, this
was associated with fewer protocol violations (0.59 (0.49–
0.72)). In 299/647 (46 %) visits, there was still protocol ad-
herence although the rheumatologist disagreed with the DAS,
as in 280/475 (59 %) visits where the rheumatologist was not
satisfied about the next treatment step and 565/736 (77 %)
visits where the rheumatologists were not satisfied with the
effect of current treatment.
When testing the five hypothetical conditions, in the BeSt-
study more protocol violations were likely if the VASgh was
≥20 mm higher than the VASphys (1.34 (1.14–1.57))
(condition 4, Table 1). In the IMPROVED-study, this associ-
ation was also found (2.18 (1.85–2.56)). In addition, the risk
of a protocol violation was also higher if the swollen joint
count (SJC) was ≤1 but tender joint count (TJC) was ≥2 (3.1
(2.73–3.52)) (condition 1, Table 1) or SJC was ≤1 and the
erythrocyte sedimentation rate (ESR) was ≥28 (1.74 (1.42–
2.14)) (condition 2, Table 1), and or SJC was ≤1 and VAS
patient was ≥20 (2.03 (1.80–2.29)) (condition 3, Table 1). In
the BeSt-study, these associations were not found.
Agreement with how the DAS represents actual disease
activity in relation to treatment targets
The rheumatologists answered that the actual disease activity
was well represented by the DAS in 87% of visits in the BeSt-
study and 83 % in the IMPROVED-study (Figs. 1c and 2c). If
misrepresentation of actual disease activity was suspected, the
Table 3 GLMM outcomes with protocol violation as dependent variable and opinions and conditions as independent variables
BeSt IMPROVED
Opinions OR 95 % CI p value OR 95 % CI p value
Not satisfied with treatment effect 1.36 1.08–1.71 0.010 0.59 0.49–0.72 <0.001
Disagreement with DAS (felt overestimation of actual disease activity) 2.26 1.84–2.78 <0.001 5.97 4.82–7.40 <0.001
Disagreement with DAS (felt underestimation of actual disease activity) 2.82 2.08–3.81 <0.001 1.44 1.01–2.07 0.047
Not satisfied next treatment step 2.77 2.34–3.28 <0.001 3.53 2.84–4.37 <0.001
Conditions
1 1.00 0.85–1.18 0.993 3.1 2.73–3.52 <0.001
2 1.03 0.80–1.33 0.826 1.74 1.42–2.14 <0.001
3 1.04 0.89–1.22 0.629 2.03 1.80–2.29 <0.001
4 1.34 1.14–1.57 <0.001 2.18 1.85–2.56 <0.001
5 1.36 1.00–1.86 0.050 0.89 0.64–1.24 0.493
DAS disease activity score, OR odds ratio, CI confidence interval
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rheumatologists mostly felt that the patient was doing better
than the DAS indicated and only rarely did they report to feel
that the measured DAS underestimated actual disease activity.
In the BeSt-study, the higher the DAS, the more likely that
rheumatologists suspected overestimation of disease activity
(by category: DAS >2.4: 97.29 (58.45–161.93), DAS ≥1.6 but
≤2.4: 9.86 (5.88–16.53)) (Table 4). Also as a continuous var-
iable, a higher DAS was associated with more reports of DAS
overestimating actual disease activity (2.97 (2.72–3.24)). In
the IMPROVED-study, a DAS ≥1.6 was more often associat-
ed with reports of overestimated actual disease activity (22.03
(16.65–29.15), for DAS as a continuous variable 3.68 (3.25–
4.16)).
Both in the BeSt-study and the IMPROVED-study, rheu-
matologists were more likely to report that the DAS
overestimated actual disease activity if VASgh was ≥20 mm
higher than the VASphys (condition 4) (Table 4). If SJC ≤1
and VASgh ≥20 mm (condition 3) (0.76 (0.64–0.91)) in the
BeSt-study DAS overestimation was less often reported, in
contrast to the IMPROVED-study where this condition was
associated with more DAS overestimation (3.03 (2.51–3.66)).
In the IMPROVED-study, the rheumatologists answered that
there was a DAS overestimation if SJC ≤1 and TJC ≥2
(condition 1) (5.65 (4.67–6.84)) and SJC ≤1 and ESR ≥28
(condition 2) (1.88 (1.39–2.55)).
DAS underestimation was filled out by the rheumatologists
if the DAS was higher in the BeSt-study (category ≥1.6–≤2.4
(1.40 (1.11–1.77)), category DAS <1.6 (0.53 (0.40–0.70)))
(Table 4). In the IMPROVED-study if the DAS was <1.6,
the rheumatologists did not feel that the DAS was
underestimating the disease activity (0.48 (0.38–0.60)).
Increase in DAS was associated with more DAS underestima-
tion in both studies (BeSt-study: 1.39 (1.25–1.55) and
IMPROVED-study 1.95 (1.70–2.25)). Condition 5
(VASphys ≥20 mm higher than VASgh) was in both studies
associated with DAS underestimation (6.73 (5.00–9.06) BeSt-
study and 8.21 (5.80–11.61) IMPROVED-study).
Satisfaction with the current treatment in relation
to treatment target
Satisfaction with the effect of the current treatment was in
88 % of the visits in the BeSt-study (Fig. 1b) and 81 % in
the IMPROVED-study (Fig. 2b). In the BeSt-study, if the
DAS was low, rheumatologists were more often satisfied with
the current treatment effect (<1.6: 76.48 (53.67–108.98) and
Table 4 GLMM outcomes with DAS over/underestimation as dependent variable and DAS and conditions as independent variables
BeSt IMPROVED
Dependent: DAS overestimation OR 95 % CI p value OR 95 % CI p value
DAS <1.6 ref ref
DAS ≥1.6–≤ 2.4 9.86 5.88–16.53 <0.001 22.03 16.65–29.15 <0.001
DAS >2.4 97.29 58.45–161.93 <0.001
DAS 2.97 2.72–3.24 <0.001 3.68 3.25–4.16 <0.001
Conditions
1 0.87 0.73–1.03 0.096 5.65 4.67–6.84 <0.001
2 1.16 0.88–1.52 0.300 1.88 1.39–2.55 <0.001
3 0.76 0.64–0.91 0.002 3.03 2.51–3.66 <0.001
4 2.96 2.51–3.49 <0.001 4.49 3.68–5.48 <0.001
Dependent: DAS underestimation
DAS <1.6 0.53 0.40–0.70 <0.001 0.48 0.38–0.60 <0.001
DAS ≥1.6–≤ 2.4 1.40 1.11–1.77 0.005 ref
DAS >2.4 ref
DAS 1.39 1.25–1.55 <0.001 1.95 1.70–2.25 <0.001
Condition
5 6.73 5.00–9.06 <0.001 8.21 5.80–11.61 <0.001
Dependent: satisfied with treatment effect
DAS <1.6 76.48 53.67–108.98 <0.001 26.06 20.68–32.84 <0.001
DAS ≥1.6–≤ 2.4 10.07 7.95–12.76 <0.001 ref
DAS >2.4 ref
DAS 0.09 0.08–0.11 <0.001 0.07 0.06–0.08 <0.001
DAS disease activity score, OR odds ratio, CI confidence interval
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≥1.6–2.4: 10.07 (7.95–12.76)) (Table 4). In the IMPROVED-
study, DAS <1.6 resulted in more satisfaction with the treat-
ment effect (26.06 (20.68–32.84)). If the DAS increased,
rheumatologists became less satisfied with the current treat-
ment effect in both studies (BeSt-study: 0.09 (0.08–0.11) and
IMPROVED-study 0.07 (0.06–0.08)).
Satisfaction with the next treatment step was 76–84 % dur-
ing the first year of the BeSt-study (Fig. 1d). During 5 years,
the satisfaction of rheumatologists with the next treatment step
increased to 86 %. In the IMPROVED-study, this question
was not asked to the rheumatologists after the second year.
During the first year, 76–86 % of the rheumatologists were
satisfied with the treatment step, and in the second year this
percentage slightly decreased to 80 % (Fig. 2d).
Discussion
Treatment-to-target is recommended for treatment of patients
with RA, but in daily practice it may be challenged by rheu-
matologists’ willingness to conform to protocolled treatment
adjustments aiming at a predefined target. Non-adherence
may diminish the effect of a treat-to-target protocol, but both
the protocol and the target may diminish adherence. In this
study, we investigated the target effect. We compared adher-
ence to two treatment protocols, one aimed at achieving low
disease activity (DAS ≤2.4, in the BeSt-study) and one aiming
at achieving DAS-remission (DAS <1.6, in the IMPROVED-
study), and found that protocol adherence was higher in the
DAS ≤2.4 targeted study. Protocol adherence decreased over
time in both studies, but more in the DAS <1.6 targeted study.
This was not particularly due to antagonism towards the re-
quired tapering of treatment as soon as DAS <1.6 was
achieved at a four-monthly evaluation time point, as we found
that protocol violations occurred more often against treatment
intensification than against tapering. In the DAS ≤2.4-steered
study, which had more delayed tapering strategies, this was
equal. In both studies, violations were associated with rheu-
matologists’ disagreement with how the measured DAS rep-
resented actual disease activity, or with the next treatment step,
and with a patient’s VASgh that was ≥20 mm higher than the
physicians VAS-disease activity. In the DAS <1.6-steered
study, apparent discrepancies between number of swollen
and painful joints measured ESR, and reported VASgh were
associated with more violations compared to the DAS ≤2.4-
steered study.
Following a protocol that aims at a stricter treatment target
is more difficult. It may be felt that there is no additional
clinical benefit to be achieved, or there are perceived risks,
for instance of side effects and/or higher costs, which may
reduce physician’s compliance. In addition, there may be
doubt whether the composite score used to measure disease
activity does represent actual disease activity [15]. This is
certainly suggested by our finding that rheumatologists report-
ed more often that they felt the measured DAS overestimated
actual disease activity in a DAS <1.6-steered treatment proto-
col compared to a DAS ≤2.4-steered treatment protocol.
When in the DAS <1.6-steered study, the DAS approaches
the target, rheumatologists also appear more sensitive to ap-
parent discrepancies between subjective and (semi)objective
representations of disease activity and reluctant to steer by
DAS alone. Still, median differences between measured
DAS and target DAS, relative to whether or not the rheuma-
tologist adhered to the protocol, may represent a tendency of
the rheumatologists to try to stay closer to the target DAS <1.6
than they did to the target DAS ≤2.4. This suggests a learning
effect, where between the start of the BeSt-study in 2000 and
the start of the IMPROVED study in 2007, rheumatologists
have conformed and became accustomed to DAS targeted
treatment and agree with the idea that DAS remission is a
target worth aiming for. In addition, they also seem to agree
that relatively rapid and complete drug tapering in patients
with early RA or undifferentiated RA, should be tried as soon
as DAS <1.6 is achieved, as protocol violations were less
often against low DAS than against high DAS.
We are the first to compare treatment targets in DAS-
steered treatment protocols in early arthritis patients by com-
paring protocol adherence and protocol violations in a long
follow-up period of 5 years, having access to two such studies
with similar technical protocols but aiming at different DAS
targets, conducted by largely the same rheumatologist. Both
studies were embedded in daily practice in the rheumatolo-
gists’ office, and our results may reflect their willingness to
conform to targeted treatment protocols outside clinical trials.
There were a lot of differences between the two studies that
make it difficult to compare them head-to-head. The
IMPROVED-study also included UA patients next to RA pa-
tients whereas in the BeSt study all patients had RA. In the
BeSt-study, patients had a more severe disease and the target
was not strict compared to the IMPROVED-study.
Furthermore, RA was associated with more low DAS-
protocol violations. This may indicate that RA is considered
as a more severe disease than UA.
Our results suggest that a DAS-steered treatment can be
implemented in daily practice. If there is a defined target, the
chance to achieve the target is eventually high. However, a
stricter treatment target is more difficult to implement in daily
practice, because rheumatologists will be content with a
slightly higher DAS if they feel it does not represent actual
disease activity. Perceived risks of the required steps may
reduce physicians’ adherence. This however can negatively
influence patient outcomes.
The COBRA study aimed at DAS-remission, and showed
comparable protocol violations during 6 months follow-up
(24 %) [16]. Recently, a sub-analysis of the NEO-RACo study
showed that physicians’ better adherence to a protocol steered
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at modified ACR remission [17] was associated with better
clinical outcomes and a lower rate of prescription of biologic
DMARD in later years [18]. Also in other diseases, physi-
cians’ adherence to a treatment protocol was associated with
better outcomes [19–22]. It is clear that a stricter DAS target
may not be achievable in all patients. Patient factors, type of
disease, comorbidities, and drug-related risks may affect com-
ponents of the DAS or prevent further treatment adjustments.
Ideally, the optimal treatment target is clear for each patient,
allowing individualized treatment. [23].
In conclusion, adherence to two DAS-steered treatment
protocols was high, but adherence decreased over 5 years.
This decrease was more distinct in a DAS <1.6 steered proto-
col, where violations were more likely if the physician
disagreed with the measured DAS. Protocol violations were
then more often against required treatment intensification than
against required tapering, whereas with a target DAS ≤2.4 this
was balanced. Also, in a DAS <1.6-steered protocol violations
occurred more often in case of potential discrepancies be-
tween detected joint swelling, pain and ESR. Our results
may indicate that adherence to DAS-steered protocols appears
to depend at least in part on the height of the target, and in
addition on how physicians perceive the DAS reflects RA
activity. Targeted treatment is important to achieve the best
possible outcomes for RA patients. It would be preferable to
combine the trend to set ever stricter treatment targets with the
benefits of an individualized approach.
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